eXmoor pharma, the full-service cell and gene therapy (CGT) manufacturing partner, and Virica Biotech Inc. (“Virica”), a leading developer of enhancers for scaling of viral vectors as well as cell and gene therapies, announced a new project funded in part through a joint Canada-UK government biomanufacturing collaboration, aimed at improving the manufacture of adeno-associated vector (AAVs), a crucial component of gene therapies. The collaborative project will utilize Virica’s VSEs™, small molecules that have been shown to increase productivity of AAVs. Source: eXmoor press release 17/1/2025